FDA clears GE HealthCare’s Allia IGS Pulse next generation of image-guided systems
GE HealthCare has gained FDA 510(k) clearance of the Allia IGS Pulse - the latest addition to the company’s image guided system (IGS)...
top of page
Browse by category
Search
Novo Nordisk to end semaglutide kidney study early due to strong efficacy signals
Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
Allurion completes AUDACITY trial enrolment for Allurion Balloon
Allurion Technologies has completed patient enrolment in its AUDACITY trial, a randomised, pivotal controlled trial designed to support...
Clinical trial of MBX 1416 for Post-Bariatric Hypoglycemia begins
The first participant has been dosed in MBX Biosciences’ Phase 1/2 clinical trial of MBX 1416, the company’s long-acting glucagon-like...
Phase III studies to investigate survodutide for people living with obesity and overweight
Boehringer Ingelheim and Zealand Pharma have initiated three Phase III trials investigating survodutide (also known as BI 456906) for...
First patient treated with SiPore21 for sustained diabetes and obesity control
The first patient has been treated with Sigrid Therapeutics’ SiPore21, an innovative medical device designed for sustained diabetes and...
European Medicines Agency to discuss anaesthesia risk for weight-loss drugs
The European Medicines Agency (EMA) will assess the risk that patients on weight loss drugs such as semaglutide and tirzepatide may...
ReShape Lifesciences signs license agreement with Biorad Medisys for Obalon Gastric Balloon
ReShape Lifesciences has signed an exclusive, royalty-bearing license agreement with Biorad Medysis (Biorad) to manufacture,...
ReShape strengthens patent portfolio related to its Obalon Balloon System
ReShape Lifesciences has strengthened the patent portfolio related to its Obalon Balloon System, after to US Patent and Trademark Office...
EMA grants Orphan Drug Designation for Setmelanotide for treatment of acquired hypothalamic obesity
The European Medicines Agency (EMA) has issued a positive opinion on the Rhythm Pharmaceuticals’ orphan drug designation request for...
Browse by tag
bottom of page